Actuate Therapeutics Announces Proposed Public Offering of Common Stock
Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company developing cancer therapies through GSK-3尾 inhibition, has announced a proposed public offering of common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of shares at the public offering price, less underwriting discounts.
The offering, managed by Lucid Capital Markets as sole book-running manager, will be conducted under an effective S-3 shelf registration. Proceeds will be used for working capital and general corporate purposes. The completion and terms of the offering are subject to market conditions.
Actuate Therapeutics (NASDAQ: ACTU), societ脿 biofarmaceutica in fase clinica che sviluppa terapie oncologiche tramite l'inibizione della GSK-3尾, ha annunciato una proposta di offerta pubblica di azioni ordinarie. L'azienda intende concedere agli sottoscrittori un opzione di 30 giorni per acquistare un ulteriore 15% delle azioni al prezzo dell'offerta pubblica, al netto degli sconti di sottoscrizione.
L'offerta, con Lucid Capital Markets in qualit脿 di unico book-running manager, sar脿 effettuata in base a un modulo S-3 gi脿 efficace. I proventi saranno destinati al capitale circolante e a scopi societari generali. Il perfezionamento e i termini dell'operazione dipendono dalle condizioni di mercato.
Actuate Therapeutics (NASDAQ: ACTU), una compa帽铆a biofarmac茅utica en fase cl铆nica que desarrolla terapias contra el c谩ncer mediante la inhibici贸n de GSK-3尾, ha anunciado una propuesta de oferta p煤blica de acciones ordinarias. La empresa planea otorgar a los colocadores una opci贸n de 30 d铆as para comprar un 15% adicional de las acciones al precio de la oferta p煤blica, menos los descuentos de suscripci贸n.
La oferta, gestionada por Lucid Capital Markets como 煤nico book-running manager, se realizar谩 bajo un registro S-3 efectivo. Los ingresos se destinar谩n a capital de trabajo y a prop贸sitos corporativos generales. La ejecuci贸n y los t茅rminos de la oferta est谩n sujetos a las condiciones del mercado.
Actuate Therapeutics (NASDAQ: ACTU)電� GSK-3尾 鞏奠牅毳� 韱淀暣 鞎� 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 旮办梾鞙茧, 氤错喌欤� 瓿店皽 毵る弰毳� 鞝滌晥頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞚胳垬鞚胳棎瓴� 瓿店皽 毵る弰 臧�瓴╈棎靹� 鞚胳垬 靾橃垬耄岆ゼ 瓿奠牅頃� 旮堨暋鞙茧 於旉皜 欤检嫕鞚� 15%毳� 毵れ垬頃� 靾� 鞛堧姅 30鞚� 鞓奠厴鞚� 攵�鞐暊 瓿勴殟鞛呺媹雼�.
鞚措矆 瓿惦電� 雼弲 攵侂煬雼� 毵る媹鞝�鞚� Lucid Capital Markets臧� 欤缄磤頃橂┌, 須牓鞚� 鞛堧姅 S-3 靹滊鞐� 霐半澕 歆勴枆霅╇媹雼�. 靾橃澋旮堨潃 鞖挫爠鞛愲掣 氚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄霅� 鞓堨爼鞛呺媹雼�. 瓿惦鞚� 鞕勲 鞐秬鞕� 甑泊鞝� 臁瓣贝鞚� 鞁滌灔 靸來櫓鞐� 霐半澕 雼澕歆戨媹雼�.
Actuate Therapeutics (NASDAQ: ACTU), une soci茅t茅 biopharmaceutique en phase clinique d茅veloppant des traitements contre le cancer via l'inhibition de la GSK鈥�3尾, a annonc茅 une offre publique propos茅e d'actions ordinaires. La soci茅t茅 pr茅voit d'accorder aux teneurs d'ordre une option de 30 jours pour acheter 15% suppl茅mentaires des actions au prix de l'offre publique, d茅duction faite des d茅cotes de souscription.
L'op茅ration, plac茅e par Lucid Capital Markets en tant qu'unique book鈥憆unning manager, sera r茅alis茅e dans le cadre d'un enregistrement S鈥�3 effectif. Les produits seront utilis茅s pour le fonds de roulement et des besoins g茅n茅raux de la soci茅t茅. La r茅alisation et les modalit茅s de l'offre d茅pendront des conditions du march茅.
Actuate Therapeutics (NASDAQ: ACTU), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Krebsbehandlungen durch GSK鈥�3尾鈥慔emmung entwickelt, hat eine vorgeschlagene 枚ffentliche Platzierung von Stammaktien angek眉ndigt. Das Unternehmen beabsichtigt, den Underwritern eine 30鈥憈盲gige Option zum Kauf von zus盲tzlichen 15% der Aktien zum Ausgabepreis abz眉glich Underwriting鈥慠abatten zu gew盲hren.
Die Emission, bei der Lucid Capital Markets als alleiniger Book鈥慠unning鈥慚anager fungiert, wird unter einer wirksamen S鈥�3鈥慞rospektregistrierung durchgef眉hrt. Die Erl枚se sollen f眉r das Working Capital und allgemeine Unternehmenszwecke verwendet werden. Abschluss und Bedingungen der Platzierung h盲ngen von den Marktbedingungen ab.
- Potential to strengthen working capital position through the offering
- Effective S-3 shelf registration already in place
- Established underwriter Lucid Capital Markets managing the offering
- Potential dilution for existing shareholders
- Uncertainty regarding offering completion and final terms
- Stock price may face pressure due to increased share supply
Insights
Actuate Therapeutics' stock offering will dilute existing shareholders while raising capital for their cancer drug development pipeline.
Actuate Therapeutics (NASDAQ: ACTU) has announced plans for a public offering of common stock, which signals the company's need to raise additional capital. This secondary offering will have a dilutive effect on existing shareholders, as new shares will be added to the market. The magnitude of dilution remains unknown since the offering size hasn't been disclosed.
The company is also granting underwriters a standard 15% overallotment option (greenshoe), which could further increase the offering size if market demand is strong. The proceeds will be used for working capital and general corporate purposes rather than a specific strategic initiative, suggesting the funds may primarily support ongoing operations and research programs.
As a clinical-stage biopharmaceutical company without marketable products, Actuate likely requires continuous capital infusions to fund its GSK-3尾 inhibitor development programs targeting difficult-to-treat cancers. This offering follows the typical financing pattern for pre-revenue biotech companies, which often tap public markets periodically to extend their operational runway.
The company has filed a shelf registration (Form S-3), indicating they've been planning this capital raise. With Lucid Capital Markets as the sole book-runner, this appears to be a relatively modest offering without a large banking syndicate, which is typical for smaller biotech financings.
CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (鈥淎ctuate鈥� or the 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3尾), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (
The Company intends to use the net proceeds from the proposed offering for working capital and general corporate purposes.
Lucid Capital Markets is acting as sole book-running manager for the offering.
The common stock described above is being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-), including a base prospectus, previously filed with and subsequently declared effective by the Securities and Exchange Commission (the 鈥淪EC鈥�). A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC鈥檚 website at聽. A final prospectus supplement describing the terms of the offering will be filed with the SEC. The offering will be made only by means of the prospectus supplement and the accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that the Company may file with the SEC. Copies of the preliminary prospectus supplement, and accompanying base prospectus relating to this offering, may be obtained from Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate鈥檚 lead investigational drug, elraglusib (a novel GSK-3尾聽inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. For additional information, please visit the Company鈥檚 website at http://www.actuatetherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding Actuate鈥檚 expectations on the timing and completion of the offering and the anticipated use of proceeds therefrom. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed under the caption 鈥淩isk Factors鈥� in the preliminary prospectus supplement related to the offering. These forward-looking statements speak only as of the date hereof. Actuate does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
[email protected]
Media Contact
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
[email protected]
[email protected]
(858) 717-2310 or (646) 942-5604
FAQ
What is the purpose of Actuate Therapeutics' (ACTU) public stock offering?
How much additional stock can underwriters purchase in ACTU's offering?
Who is managing Actuate Therapeutics' (ACTU) public offering?
What is Actuate Therapeutics' main focus as a company?
How can investors access the prospectus for ACTU's stock offering?
